GDOC holdings
All 42 positions of Goldman Sachs Future Health Care Equity ETF.
Positions
42
Top 10 weight
57.3%
Effective holdings
20.1
1 / sum of squared weights
In stocks
98.5%
In bonds
0.0%
Outside the US
23.7%
Asset mix
Sectors
82% of stocks classifiedCountries
Holdings
| # | Holding | Type | Weight | Value | Shares / par | Country |
|---|---|---|---|---|---|---|
| 1 | LLYEli Lilly & Co. | Equity | 13.28% | $2.7M | 2,417 | US |
| 2 | JNJJohnson & Johnson | Equity | 8.07% | $1.6M | 7,204 | US |
| 3 | MRKMerck & Co., Inc. | Equity | 5.94% | $1.2M | 10,073 | US |
| 4 | GHGuardant Health, Inc. Common Stock | Equity | 5.34% | $1.1M | 8,286 | US |
| 5 | ASTRAZENECA PLC | Equity | 4.84% | $974K | 5,234 | GB |
| 6 | TMOThermo Fisher Scientific, Inc. | Equity | 4.52% | $910K | 1,847 | US |
| 7 | ARGXargenx SE American Depositary Shares | Equity | 4.07% | $818K | 979 | NL |
| 8 | ISRGIntuitive Surgical Inc. | Equity | 3.90% | $785K | 1,849 | US |
| 9 | BSXBoston Scientific Corp. | Equity | 3.78% | $760K | 15,740 | US |
| 10 | HOYA CORP | Equity | 3.53% | $710K | 4,173 | JP |
| 11 | EWEdwards Lifesciences Corp | Equity | 2.98% | $600K | 6,939 | US |
| 12 | LONZA GROUP AG | Equity | 2.80% | $563K | 879 | CH |
| 13 | DXCMDexCom, Inc. | Equity | 2.79% | $562K | 7,621 | US |
| 14 | AAgilent Technologies Inc. | Equity | 2.77% | $556K | 4,105 | US |
| 15 | ROIVANT SCIENCES LTD | Equity | 2.39% | $481K | 16,036 | BM |
| 16 | CORCencora, Inc. | Equity | 2.34% | $471K | 1,750 | US |
| 17 | APGEApogee Therapeutics, Inc. Common Stock | Equity | 1.97% | $396K | 4,823 | US |
| 18 | ROYALTY PHARMA PLC | Equity | 1.77% | $355K | 6,370 | GB |
| 19 | PENPenumbra, Inc. | Equity | 1.61% | $323K | 1,015 | US |
| 20 | MTDMettler-Toledo International | Equity | 1.59% | $320K | 271 | US |
| 21 | VRTXVertex Pharmaceuticals Inc | Equity | 1.48% | $299K | 667 | US |
| 22 | GOLDMAN SACHS TRUST | Cash | 1.43% | $288K | 287,989 | US |
| 23 | CYTKCytokinetics Inc. | Equity | 1.40% | $281K | 3,663 | US |
| 24 | IONSIonis Pharmaceuticals, Inc. Common Stock | Equity | 1.37% | $276K | 3,614 | US |
| 25 | XENEXenon Pharmaceuticals Inc | Equity | 1.35% | $272K | 4,977 | CA |
| 26 | UNHUNITEDHEALTH GROUP INCORPORATED (Delaware) | Equity | 1.35% | $272K | 715 | US |
| 27 | RGENRepligen Corp | Equity | 1.26% | $253K | 2,038 | US |
| 28 | INSMInsmed, Inc. | Equity | 1.11% | $222K | 2,081 | US |
| 29 | GALDERMA GROUP AG | Equity | 1.10% | $220K | 1,034 | CH |
| 30 | MDGLMadrigal Pharmaceuticals, Inc. Common Stock | Equity | 1.06% | $214K | 430 | US |
| 31 | RVMDRevolution Medicines, Inc. Common Stock | Equity | 0.84% | $168K | 1,069 | US |
| 32 | CGONCG Oncology, Inc. Common stock | Equity | 0.75% | $151K | 2,432 | US |
| 33 | BBIOBridgeBio Pharma, Inc. Common Stock | Equity | 0.73% | $147K | 2,214 | US |
| 34 | DGXQuest Diagnostics Inc. | Equity | 0.72% | $144K | 741 | US |
| 35 | RYTMRhythm Pharmaceuticals, Inc. Common Stock | Equity | 0.68% | $136K | 1,538 | US |
| 36 | ALKERMES PLC | Equity | 0.57% | $114K | 2,703 | IE |
| 37 | SARTORIUS STEDIM BIOTECH SA | Equity | 0.55% | $111K | 533 | FR |
| 38 | PRAXPraxis Precision Medicines, Inc. Common Stock | Equity | 0.55% | $111K | 316 | US |
| 39 | DFTXDefinium Therapeutics, Inc. Common Shares | Equity | 0.51% | $102K | 4,214 | CA |
| 40 | SYRESpyre Therapeutics, Inc. Common Stock | Equity | 0.35% | $71K | 960 | US |
| 41 | PODDInsulet Corporation | Equity | 0.29% | $58K | 398 | US |
| 42 | GPCRStructure Therapeutics Inc. American Depositary Shares | Equity | 0.20% | $40K | 1,008 | KY |
Find which other funds hold a stock by opening it and choosing "ETFs holding".
Position changes between reports
| Action | Holding | Weight before | Weight after | Shares vs flows | Between reports |
|---|---|---|---|---|---|
| Exit | ABTAbbott Laboratories | 3.13% | — | — | Feb 28, 2026 → May 31, 2026 SEC |
| New position | EWEDWARDS LIFESCIENCES CORP | — | 2.98% | — | Feb 28, 2026 → May 31, 2026 SEC |
| Decrease | ASTRAZENECA PLC | 6.40% | 4.84% | −18.1% | Feb 28, 2026 → May 31, 2026 SEC |
| New position | VRTXVERTEX PHARMACEUTICALS INC | — | 1.48% | — | Feb 28, 2026 → May 31, 2026 SEC |
| Exit | QIAGEN NV | 1.39% | — | — | Feb 28, 2026 → May 31, 2026 SEC |
| New position | GALDERMA GROUP AG | — | 1.10% | — | Feb 28, 2026 → May 31, 2026 SEC |
| Exit | NTRANATERA INC | 1.05% | — | — | Feb 28, 2026 → May 31, 2026 SEC |
| Decrease | SARTORIUS STEDIM BIOTECH SA | 1.59% | 0.55% | −65.2% | Feb 28, 2026 → May 31, 2026 SEC |
| Exit | ACLXArcellx Inc | 0.82% | — | — | Feb 28, 2026 → May 31, 2026 SEC |
| Increase | ROYALTY PHARMA PLC | 1.01% | 1.77% | +39.8% | Feb 28, 2026 → May 31, 2026 SEC |
| New position | DGXQUEST DIAGNOSTICS INC | — | 0.72% | — | Feb 28, 2026 → May 31, 2026 SEC |
| Exit | WGSGeneDx Holdings Corp | 0.59% | — | — | Feb 28, 2026 → May 31, 2026 SEC |
| New position | ALKERMES PLC | — | 0.57% | — | Feb 28, 2026 → May 31, 2026 SEC |
| New position | PRAXPRAXIS PRECISION MEDICINES INC | — | 0.55% | — | Feb 28, 2026 → May 31, 2026 SEC |
| New position | DFTXDEFINIUM THERAPEUTICS INC | — | 0.51% | — | Feb 28, 2026 → May 31, 2026 SEC |
| Increase | PENPENUMBRA INC | 1.14% | 1.61% | +46.6% | Feb 28, 2026 → May 31, 2026 SEC |
| Increase | CYTKCYTOKINETICS INC | 0.98% | 1.40% | +11.9% | Feb 28, 2026 → May 31, 2026 SEC |
| Exit | RAREUltragenyx Pharmaceuticals Inc | 0.37% | — | — | Feb 28, 2026 → May 31, 2026 SEC |
| New position | SYRESPYRE THERAPEUTICS INC | — | 0.35% | — | Feb 28, 2026 → May 31, 2026 SEC |
| Decrease | RYTMRHYTHM PHARMACEUTICALS INC | 0.88% | 0.68% | −22.5% | Feb 28, 2026 → May 31, 2026 SEC |
| Decrease | BBIOBRIDGEBIO PHARMA INC | 0.92% | 0.73% | −23.0% | Feb 28, 2026 → May 31, 2026 SEC |
| Decrease | AAGILENT TECHNOLOGIES INC | 2.90% | 2.77% | −17.8% | Feb 28, 2026 → May 31, 2026 SEC |
| Increase | INSMINSMED INC | 1.22% | 1.11% | +22.1% | Feb 28, 2026 → May 31, 2026 SEC |
| Decrease | CGONCG ONCOLOGY INC | 0.83% | 0.75% | −17.3% | Feb 28, 2026 → May 31, 2026 SEC |
| New position | MRKMerck & Co., Inc | — | 5.98% | — | Nov 30, 2025 → Feb 28, 2026 SEC |
| Decrease | PODDInsulet Corporation | 3.81% | 0.47% | −84.2% | Nov 30, 2025 → Feb 28, 2026 SEC |
| Exit | NBIXNeurocrine Biosciences Inc | 2.37% | — | — | Nov 30, 2025 → Feb 28, 2026 SEC |
| Exit | VEEVVeeva Systems Inc | 1.93% | — | — | Nov 30, 2025 → Feb 28, 2026 SEC |
| Exit | DHRDanaher Corp | 1.70% | — | — | Nov 30, 2025 → Feb 28, 2026 SEC |
| Exit | Novo Nordisk A/S | 1.53% | — | — | Nov 30, 2025 → Feb 28, 2026 SEC |
| Decrease | ABTAbbott Laboratories | 4.62% | 3.13% | −27.9% | Nov 30, 2025 → Feb 28, 2026 SEC |
| New position | IONSIonis Pharmaceuticals, Inc. | — | 1.41% | — | Nov 30, 2025 → Feb 28, 2026 SEC |
| New position | QIAGEN NV | — | 1.39% | — | Nov 30, 2025 → Feb 28, 2026 SEC |
| Increase | DXCMDexCom Inc | 1.37% | 2.68% | +63.1% | Nov 30, 2025 → Feb 28, 2026 SEC |
| New position | RGENRepligen Corporation | — | 1.26% | — | Nov 30, 2025 → Feb 28, 2026 SEC |
| New position | PENPenumbra Inc. | — | 1.14% | — | Nov 30, 2025 → Feb 28, 2026 SEC |
| New position | Royalty Pharma PLC | — | 1.01% | — | Nov 30, 2025 → Feb 28, 2026 SEC |
| Exit | ALNYAlnylam Pharmaceuticals Inc | 0.97% | — | — | Nov 30, 2025 → Feb 28, 2026 SEC |
| New position | BBIOBridgebio Pharma Inc | — | 0.92% | — | Nov 30, 2025 → Feb 28, 2026 SEC |
| Decrease | MDGLMadrigal Pharmaceuticals Inc | 1.78% | 0.89% | −33.5% | Nov 30, 2025 → Feb 28, 2026 SEC |
| Exit | IRTCiRhythm Technologies Inc | 0.74% | — | — | Nov 30, 2025 → Feb 28, 2026 SEC |
| Exit | WSTWest Pharmaceutical Services I | 0.69% | — | — | Nov 30, 2025 → Feb 28, 2026 SEC |
| Increase | RYTMRhythm Pharmaceuticals Inc | 0.46% | 0.88% | +115.0% | Nov 30, 2025 → Feb 28, 2026 SEC |
| Increase | APGEApogee Therapeutics Inc. | 1.22% | 1.62% | +31.0% | Nov 30, 2025 → Feb 28, 2026 SEC |
| Decrease | RVMDRevolution Medicines Inc | 0.87% | 0.52% | −56.1% | Nov 30, 2025 → Feb 28, 2026 SEC |
| New position | GPCRStructure Therapeutics Inc | — | 0.30% | — | Nov 30, 2025 → Feb 28, 2026 SEC |
| Increase | CGONCG Oncology Inc. | 0.53% | 0.83% | +14.7% | Nov 30, 2025 → Feb 28, 2026 SEC |
| Increase | GHGuardant Health Inc | 3.53% | 3.73% | +17.4% | Nov 30, 2025 → Feb 28, 2026 SEC |
Share-count changes are measured after removing what creations and redemptions explain.
Fund data comes from each fund's SEC filings and issuer disclosures and is shown with the date it is as of. SEC portfolio and flow filings become public about 60 days after the period they cover. Nothing here is investment advice; see Terms.